Hormone receptor (HR)‐positive and human epidermal growth factor receptor 2 (HER2)‐
negative breast cancer is defined by the presence of the estrogen receptor and/or the …

Despite recent therapeutic advances in cancer treatment, metastasis remains the principal
cause of cancer death. Recent work has uncovered the unique biology of metastasis …

Breast cancer is treated with a multidisciplinary approach involving surgical oncology,
radiation oncology, and medical oncology. The NCCN Clinical Practice Guidelines in …

Background Adjuvant and neoadjuvant breast cancer treatments can reduce breast cancer
mortality but may increase mortality from other causes. Information regarding treatment …

Breast cancer is the leading cause of death from cancer in women worldwide, and the
second most common cause of death from cancer in women in the United States. Risk …

Despite decades of laboratory, epidemiological and clinical research, breast cancer
incidence continues to rise. Breast cancer remains the leading cancer-related cause of …

Background For women with early-stage oestrogen receptor (ER)-positive breast cancer,
adjuvant tamoxifen reduces 15-year breast cancer mortality by a third. Aromatase inhibitors …

In 2018, the predicted number of new breast cancers in 28 European Union (EU) countries
was 404 920, with estimated age-adjusted annual incidence of breast cancer of 144.9/100 …

Metastatic dissemination occurs very early in the malignant progression of a cancer but the
clinical manifestation of metastases often takes years. In recent decades, 5-year survival of …

Skeletal metastases are frequent complications of many cancers, causing bone
complications (fractures, bone pain, disability) that negatively affect the patient's quality of …